KR101961601B1 - 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법 - Google Patents

바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법 Download PDF

Info

Publication number
KR101961601B1
KR101961601B1 KR1020187002212A KR20187002212A KR101961601B1 KR 101961601 B1 KR101961601 B1 KR 101961601B1 KR 1020187002212 A KR1020187002212 A KR 1020187002212A KR 20187002212 A KR20187002212 A KR 20187002212A KR 101961601 B1 KR101961601 B1 KR 101961601B1
Authority
KR
South Korea
Prior art keywords
hbv
compound
group
virus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187002212A
Other languages
English (en)
Korean (ko)
Other versions
KR20180014179A (ko
Inventor
청 케이. 추
지아닝 왕
Original Assignee
유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 filed Critical 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드
Publication of KR20180014179A publication Critical patent/KR20180014179A/ko
Application granted granted Critical
Publication of KR101961601B1 publication Critical patent/KR101961601B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187002212A 2009-11-16 2010-11-16 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법 Expired - Fee Related KR101961601B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28134209P 2009-11-16 2009-11-16
US61/281,342 2009-11-16
PCT/US2010/056808 WO2011060408A2 (en) 2009-11-16 2010-11-16 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127015444A Division KR101840479B1 (ko) 2009-11-16 2010-11-16 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법

Publications (2)

Publication Number Publication Date
KR20180014179A KR20180014179A (ko) 2018-02-07
KR101961601B1 true KR101961601B1 (ko) 2019-03-25

Family

ID=43992463

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187002212A Expired - Fee Related KR101961601B1 (ko) 2009-11-16 2010-11-16 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
KR1020127015444A Expired - Fee Related KR101840479B1 (ko) 2009-11-16 2010-11-16 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127015444A Expired - Fee Related KR101840479B1 (ko) 2009-11-16 2010-11-16 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법

Country Status (14)

Country Link
US (1) US8946244B2 (enExample)
EP (1) EP2501709A4 (enExample)
JP (1) JP5779799B2 (enExample)
KR (2) KR101961601B1 (enExample)
CN (1) CN102725302B (enExample)
AP (1) AP2012006310A0 (enExample)
AU (1) AU2010319999B2 (enExample)
CA (1) CA2781054A1 (enExample)
EA (1) EA201270632A1 (enExample)
IL (1) IL219748A0 (enExample)
MX (1) MX2012005601A (enExample)
PH (1) PH12012500963B1 (enExample)
WO (1) WO2011060408A2 (enExample)
ZA (1) ZA201204356B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN102850402B (zh) * 2011-06-28 2016-08-03 李勤耕 非环核苷环状磷酸酯类衍生物，其制备方法及医药用途
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
CN102603652A (zh) * 2011-12-27 2012-07-25 河南师范大学 5-甲酰基嘧啶碳环核苷及制备方法
MD20140094A2 (ro) * 2012-02-14 2015-03-31 University Of Georgia Research Foundation, Inc. Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
CN103804417B (zh) * 2012-11-13 2017-09-19 北京美倍他药物研究有限公司 抗乙肝病毒药物
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CA2898092A1 (en) * 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US9334273B1 (en) 2014-03-05 2016-05-10 University Of Georgia Research Foundation, Inc. Efficient and stereoselective synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA)
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN106466300B (zh) * 2015-08-12 2019-06-21 复旦大学 一种装载难溶性药物的复合壳聚糖纳米粒制剂及其制备方法和应用
WO2017127461A1 (en) * 2016-01-18 2017-07-27 Sensor Electronic Technology, Inc. Semiconductor device with improved light propagation
US10987372B2 (en) 2016-03-11 2021-04-27 Kagoshima University Anti-hepatoma-virus agent
US10533008B2 (en) * 2016-04-07 2020-01-14 University Of Georgia Research Foundation, Inc. Synthesis of 2′-fluoro-6′-methylene-carbocyclic adenosine (FMCA) and 2′-fluoro-6′-methylene-carbocyclic guanosine (FMCG)
US10653678B2 (en) 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
SG11201808402RA (en) 2016-04-11 2018-10-30 Genfit Methods of treatment for cholestatic and fibrotic diseases
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PL3512863T3 (pl) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
WO2018092728A1 (ja) * 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
WO2018133835A1 (en) * 2017-01-20 2018-07-26 National Institute Of Biological Sciences, Beijing Nucleoside analogue regulating mammalian circadian rhythm
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
JP7496132B2 (ja) * 2018-08-31 2024-06-06 国立大学法人 鹿児島大学 核酸アナログ及び抗ｂ型肝炎ウイルス剤
CN109846887B (zh) * 2019-03-22 2022-12-09 南京大学 2-氨基嘌呤-6（h）硫酮在制备单纯疱疹病毒的抑制剂中的应用
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
BR112023026356A2 (pt) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396623A (en) 1981-08-26 1983-08-02 Southern Research Institute Carbocyclic analogs of uracil nucleosides as antiviral agents
US20020016980A1 (en) 2000-05-10 2002-02-07 Alberte Randall S. Transgenic plants incorporating traits of zostera marina
US20070042940A1 (en) * 2002-06-28 2007-02-22 Lacolla Paola Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520553D0 (en) * 1985-08-16 1985-09-25 Glaxo Group Ltd Chemical compound
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
CN1268345C (zh) * 2000-03-29 2006-08-09 乔治敦大学 治疗丁型肝炎病毒感染的核苷化合物
HUP0400726A3 (en) * 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004002422A2 (en) * 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396623A (en) 1981-08-26 1983-08-02 Southern Research Institute Carbocyclic analogs of uracil nucleosides as antiviral agents
US20020016980A1 (en) 2000-05-10 2002-02-07 Alberte Randall S. Transgenic plants incorporating traits of zostera marina
US20070042940A1 (en) * 2002-06-28 2007-02-22 Lacolla Paola Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections

Also Published As

Publication number Publication date
WO2011060408A3 (en) 2011-10-13
AU2010319999B2 (en) 2014-01-16
KR20180014179A (ko) 2018-02-07
PH12012500963B1 (en) 2018-08-10
AP2012006310A0 (en) 2012-06-30
JP2013510904A (ja) 2013-03-28
ZA201204356B (en) 2013-02-27
PH12012500963A1 (en) 2018-05-15
US20130005677A1 (en) 2013-01-03
KR101840479B1 (ko) 2018-03-20
WO2011060408A2 (en) 2011-05-19
JP5779799B2 (ja) 2015-09-16
CN102725302A (zh) 2012-10-10
HK1172628A1 (zh) 2013-04-26
AU2010319999A1 (en) 2012-06-21
CN102725302B (zh) 2016-04-06
CA2781054A1 (en) 2011-05-19
EP2501709A2 (en) 2012-09-26
MX2012005601A (es) 2012-08-01
US8946244B2 (en) 2015-02-03
KR20120092153A (ko) 2012-08-20
EP2501709A4 (en) 2013-11-13
IL219748A0 (en) 2012-07-31
EA201270632A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
KR101961601B1 (ko) 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
KR102002886B1 (ko) 2’-플루오로-6’-메틸렌 탄소환 뉴클레오시드 및 바이러스 감염을 치료하는 방법
US11082386B2 (en) 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
US11760761B2 (en) Methods and compositions for targeting PD-L1
US8673926B2 (en) Spiro[2.4]heptanes for treatment of flaviviridae infections
EA026523B1 (ru) 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения
CN119212987A (zh) 用于靶向pd-l1的方法和组合物
KR20230157446A (ko) ETV (Entecavir) 의 항 바이러스 전구약물들 및 이의 제제들 (FORMULATIONS)
HK1172628B (en) 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
HK1194385B (en) 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections
HK1194385A (en) 2'-fluoro-6'-methylene carbocyclic nuceosides and methods of treating viral infections

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20240319

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240319

St.27 status event code: N-4-6-H10-H13-oth-PC1903